Korea:009420

HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update

* Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. * R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-mediated autoimmune diseases. * Anticip...

2024-03-21 19:00 1044

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum

ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...

2023-12-20 20:00 1205

HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors

WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...

2023-12-11 20:00 1049

HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, due to the sustained growth of major products. * 'HL161ANS', HanAll's second anti-FcRn antibody, demonstrated best-in-class potential through the initial outcome of Phase 1 study. * 'HL192', a Nu...

2023-10-26 19:00 1288

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192

* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. * The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of ...

2023-10-12 19:00 1137

HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sustained robust growth of major products in addition to milestone revenues from the progress in clinical programs of batoclimab. * Multiple clinical development milestones have been reached, includin...

2023-07-27 19:00 1713

HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's Disease

* HanAll Biopharma and Daewoong Pharmaceutical have co-invested in Vincere Biosciences. * These mission-aligned companies are collaborating to develop small-molecule therapies for Parkinson's patients, benefiting from their combined expertise in clinical development and disease biology. * T...

2023-06-12 19:00 2298

HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease

* HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders * Phase 1 clinical trial is ex...

2023-05-25 19:00 2091

HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease

* Tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score (CCSS) or in improvement in Eye Dryness Score (EDS) assessed at week 8 in subjects with dry eye disease (DED), compared to vehicle. * However,...

2023-05-19 19:00 1853

HanAll Biopharma Reports First Quarter Results and Provides Business Update

* Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022 * HanAll made a strong start to 2023 with positive Phase 3 study results of anti-FcRn asset batoclimab for the treatment of generalized myasthenia gravis in C...

2023-04-28 19:00 2738

HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth

* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales * Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmace...

2023-03-29 19:00 1259

HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program

* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...

2023-03-15 19:00 1642

HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...

2023-03-06 20:00 1402

HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities

* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders * Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder SEOUL, So...

2023-02-10 20:00 2755

HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update

* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...

2023-02-01 20:00 1703

HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update

* Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfolio expansion and strong sales in major products * R&D expenses for the quarter increased by 63%, reflecting the preparation of a Phase 3 study i...

2022-11-15 20:00 1243

HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab

* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...

2022-10-11 19:00 1053

HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...

2022-10-04 19:00 1189

HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update

* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division   * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...

2022-07-29 20:00 2758

HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update

* HanAll will expand R&D investments to advance its late-stage pipeline assets   SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe unmet medical needs, tod...

2022-04-28 19:00 1394
12

Week's Top Stories